| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Glabrescione B (GlaB) was extracted and purified from seeds of Derris glabrescens (Leguminosae) Glabrescione B — Glabrescione B (GlaB) is a naturally occurring isoflavone-derived small molecule originally isolated from the seeds of Derris glabrescens. It is classified as a direct GLI transcription-factor inhibitor and experimental Hedgehog-pathway antagonist. Unlike clinically used Smoothened inhibitors, GlaB acts downstream of SMO by binding the zinc-finger DNA-binding region of GLI1 and disrupting GLI1-DNA interaction. This downstream mechanism is potentially relevant to tumors with canonical or non-canonical GLI1 activation and to resistance mechanisms that bypass SMO. GlaB remains an experimental preclinical compound rather than an approved anticancer drug. Primary mechanisms (ranked):
Bioavailability / PK relevance: Free GlaB has poor aqueous solubility and unfavorable formulation characteristics that substantially limit systemic translation. Nanocarrier approaches, including polymeric nanocapsules, self-assembling mPEG-cholane micelles, and liposomes, have been developed to improve solubility, circulation exposure, tumor delivery, and pharmacokinetics. In mouse models, micellar GlaB achieved longer systemic exposure and delivery across the blood-brain barrier; newer liposomal formulations produced higher exposure and slower elimination than free GlaB. In-vitro vs systemic exposure relevance: Many mechanistic experiments use approximately 1–10 µM GlaB for 24–72 hours. These concentrations should not be assumed to be achievable or maintainable with unformulated systemic GlaB. The major translational issue is therefore drug delivery rather than evidence that oral or conventional systemic dosing can reproduce standard in-vitro concentrations. Nanocarrier formulation materially changes this exposure constraint. Clinical evidence status: Preclinical only. Antitumor activity has been demonstrated in cultured cells, cancer stem-cell assays, xenografts, orthotopic medulloblastoma models, patient-derived renal cancer organoids, and other animal models. No human therapeutic trial of Glabrescione B and no FDA, EMA, or Health Canada approval were identified as of August 2026. Current development remains focused on formulation, pharmacokinetics, and preclinical validation. Glabrescione B Cancer-Relevant Mechanisms
|
| Source: |
| Type: protein/gene |
| The GLI gene family consists of three members: GLI1, GLI2, and GLI3. These genes encode transcription factors that play crucial roles in the Hedgehog signaling pathway, which is important for various developmental processes and cellular functions. : In many cancers, aberrant activation of the Hedgehog signaling pathway leads to increased GLI expression. This can occur through mutations in Hedgehog pathway components or through the overexpression of Hedgehog ligands. -GLI factors are implicated in maintaining cancer stem cell populations. These cells often drive tumor recurrence, metastasis, and resistance to therapy because they have self-renewal capabilities. The overactivation of GLI may, therefore, help sustain these subpopulations within tumors. Elevated GLI expression levels can serve as a prognostic marker in certain cancers, indicating a more aggressive disease and poorer outcomes. |
| 7300- | GlaB, | ATO, | Targeting GLI1 and GLI2 with small molecule inhibitors to suppress GLI-dependent transcription and tumor growth |
| - | in-vitro, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:90 Target#:434 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid